The FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News ODAC Votes in Favor of Continued Development of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer back to News
The FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.